Allarity Therapeutics Inc (ALLR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.18 (+1.72%), Market cap $0.02B, 52-week low–high $0.80 ~ $1.97.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemot
Financial statements, price targets, institutional (13F) holdings and related news for Allarity Therapeutics Inc are updated in real time on BlackAll Trade.
Allarity Therapeutics Inc trades at $1.18 (+1.72%). Real-time quotes and charts are available on BlackAll Trade.
Allarity Therapeutics Inc has a market cap of about $0.02B.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United